Real World Asparaginase Therapy Toxicity

Official record

Identifier

NCT07008027

Recruiting locations

country

United States

Interventions studied

Not provided in the official record

Lead sponsor

St. Jude Children's Research Hospital

Target enrolment

200 participants

Study type

OBSERVATIONAL

Phase

Not provided in the official record

Status

Not yet recruiting

First posted

Jun 6, 2025

Last updated on the registry

Sep 17, 2026

Age

Not provided in the official record

Sex

ALL

Study contact

The official record lists a study contact. Contact details are published there and are intentionally not copied to this page.

Eligibility criteria

Reproduced verbatim from the official record. Eligibility is decided by the study team, never by this page.

Inclusion Criteria:

* Diagnosis of acute lymphoblastic leukemia, lymphoblastic lymphoma, or mixed phenotype acute leukemia
* Enrolled on INITIALL and no more than 10 days after initiation of post-INITIALL therapy
* Post-INITIALL therapy is:

  * Standard of Care (SOC)/Non Protocol Treatment Plan (NPTP) as per Total therapy or
  * SJALL23T and not scheduled to receive venetoclax

Exclusion Criteria:

* Inability or unwillingness of research participant or legal guardian/representative to give written informed consent.

Indexed under

Leukemia